NPCE's RNS adoption, new indications and reimbursement gains offer growth potential, but weak sales execution and regulatory hurdles pose near-term risks.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mio USD) | Schätzung (Mio USD) | Abweichung |
|---|